Evidence map›Paper›PMID 29340221›Full record

ArticleActa naturae

Recombinant Antibodies to the Ebola Virus Glycoprotein.

A A Panina, I G Dementieva, T K Aliev, V A Toporova, D S Balabashin, M N Bokov, L P Pozdnyakova, O B Shchemchukova, D A Dolgikh, P G Sveshnikov and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

A A PaninaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Mikluho- Maclay Str. 16/10, Moscow, 117997, Russia.
I G DementievaRussian Scientific Center for Molecular Diagnosis and Treatment, Simferopol Blvd. 8, Moscow, 117149 , Russia.
T K AlievLomonosov Moscow State University, Department of Chemistry, Leninskie gory 1, bldg. 3, Moscow, 119991, Russia.
V A ToporovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Mikluho- Maclay Str. 16/10, Moscow, 117997, Russia.
D S BalabashinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Mikluho- Maclay Str. 16/10, Moscow, 117997, Russia.
M N BokovRussian Scientific Center for Molecular Diagnosis and Treatment, Simferopol Blvd. 8, Moscow, 117149 , Russia.
L P PozdnyakovaRussian Scientific Center for Molecular Diagnosis and Treatment, Simferopol Blvd. 8, Moscow, 117149 , Russia.
O B ShchemchukovaRussian Scientific Center for Molecular Diagnosis and Treatment, Simferopol Blvd. 8, Moscow, 117149 , Russia.
D A DolgikhShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Mikluho- Maclay Str. 16/10, Moscow, 117997, Russia.
P G SveshnikovRussian Scientific Center for Molecular Diagnosis and Treatment, Simferopol Blvd. 8, Moscow, 117149 , Russia.
M P KirpichnikovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Mikluho- Maclay Str. 16/10, Moscow, 117997, Russia.
Russian Research Center for Molecular Diagnostics and Therapy · RUInstitute of Bioorganic Chemistry · BYInstitute of Bioorganic Chemistry · RULomonosov Moscow State University · RUMoscow State University · TJ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, there are no approved therapies for targeted prevention and treatment of Ebola hemorrhagic fever. In the present work, we describe the development of a eukaryotic expression system for the production of three full-length chimeric antibodies (IgG1-kappa isotypes) GPE118, GPE325, and GPE534 to the recombinant glycoprotein of the Ebola virus (EBOV GP), which is a key factor in the pathogenicity of the disease. The immunochemical properties of the obtained antibodies were studied by immunoblotting and indirect, direct, and competitive ELISA using the recombinant EBOV proteins rGPdTM, NP, and VP40. The authenticity of the antibodies and the absence of cross-specificity with respect to the structural proteins NP and VP40 of the Ebola virus were proved. The epitope specificity of the resulting recombinant antibodies was studied using commercial neutralizing antibodies against the viral glycoprotein. The recombinant antibodies GPE118, GPE325, and GPE534 were shown to recognize glycoprotein epitopes that coincide or overlap with the epitopes of three well-studied neutralizing anti-Ebola virus antibodies.

Indexed as

Ebola hemorrhagic fever virustherapeutic recombinant chimeric antibodies

Identifiers

PMID29340221
PMCPMC5762832
OpenAlexW2918229946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.